The regular Mass Spec market is being challenged by a new wave of companies whose technologies aim to disrupt the well-established market of large Mass Spec instrument vendors. These regular MS instruments tend to be expensive to buy, although not that expensive to run. There are limitations in the type of analysis one can perform with regular Mass Spec. One of the biggest limitations is that performing 'de novo' protein sequencing in MS is not straightforward: the most common way is to digest the proteins into small peptides, and then

In #biotech #stocks news, today we review $TXG @10xGenomics , one of the companies in the #SingleCell and #SpatialBiology sectors. 10x Genomics is a biotechnology company that develops and markets solutions for omics analysis of single cell and spatial biology samples. The company offers several product lines:

As we see videos in social media of the first $PACB PacBio Revio to enter the @broadinstitute , with the promise of the long-read $1000/genome in place, what does it look like today to set up a Next-Generation Sequencing factory/institute?

https://twitter.com/AlbertVilella/status/1624465272496168965

There have been many of these institutes come and go, and probably the @broadinstitute (Cambridge, US) and the @sangerinstitute (Cambridge, UK) are the two referents in historical terms and in their magnitude of achievements in #genomics. So if we take them as an example, what do

One of the rather big announcements by $BLI Berkeley Lights (soon to be renamed PhenomeX) is that there would be a new Beacon instrument released in 2023: the Beacon Quest, a 2-chip optofluidic system for academic research. Those of you that have been reading this account for a while will remember that the Beacon is a multi-million dollar large-fridge/freezer instrument that does high-throughput single-cell phenotyping, and the main product in the product line for Berkeley Lights (PhenomeX).

In #NextGenerationSequencing news, $ILMN Illumina has some more details on the website for the NextSeq 1000/2000 kits, now including a 100 cycle kit for the P1 flowcells, and the 600 cycle kits for P1 and P2. The interesting detail is that the P2 600 cycles kit gives 300M Reads CPF (Clusters passing filter), compared to the equivalent 300 cycle kit on the same flowcell (400M). So either the diameter of the wells is different, or about 100M Clusters are "lost" in the 600 cycle kit.

The world of Next-Generation Sequencing (NGS) post-#AGBT23:
1) Some will say that $ILMN Illumina is sleep-walking into a cliff: the company has been dominating the field with 80-90%+ of the market-share, but they are unable to retain their technological advantage to competitors: - Illumina doesn't have the most affordable $/Gb platform anymore, currently at $3.2/Gb, and $2/Gb in H2 2023, but others are already at $2/Gb, $1.5/Gb and will be at $1/Gb in Q3 2023.

A summary of announcements/highlights from #AGBT23 (in no particular order): #AGBT23 cfDNA methylation profiling as a blood biomarker for Congestive Heart Failure. This is from the same team that gave you the @GrailBio Methylation Atlas, now applied to biomarker discovery. genomeweb.com/sequencing/agb…

In #NextGenerationProteomics news, today we cover the basics of Proximity ligation assay (PLA) technology, also known as proximity barcoding assay technology, which is a method for detecting protein-protein interactions in cells or tissues. The assay is based on the principle of ligating two probes (such as antibodies) that are in close proximity to each other, typically within a few nanometers. The ligation reaction produces a circular DNA molecule that is amplified by polymerase chain reaction (PCR) and

#AGBT23 More details on the $ILMN Illumina Infinity reads technology from Alex Aravanis (post from LinkedIn). Also first data shared on XLEAP-SBS chemistry for the NextSeq 1000/2000 instruments. Not sure why would anyone buy one of these instruments given the alternatives from @ElemBio and @CompleteGenomic 's G400.

Given all the talk of $100 genomes and tens of thousands of genomes being sequenced per year on a single instrument, the question arises: how many of these sequencing factories are we going to see? how many genome equivalents do we need capacity for? Taking the 50,000 genomes a year mark as a starting number, and considering we have 140 million new-borns a year, we would need 2,800 DNBSEQ T20 factories distributed around the world only to keep up with the new-born human population.

In #NextGenerationSequencing, @CompleteGenomic's new of the <$100/genome with their DNBSEQ T20 available from Q3 2023, and their T7x3 $130/genome pricing, we now have 3 companies that have hit the $200/genome mark with announcements: @ElemBio $ILMN Illumina and Complete Genomics. Both $ILMN Illumina and @CompleteGenomic's will hit the $200/genome and <$100/genome mark in the second half of 2023, but @ElemBio Element Bio AVITIx3 and Complete Genomics T7x3 pricing models are *now* available at $200/genome and $130/genome respectively.

In #JPM2023, $NAUT Nautilus Bio didn't make their slides available, but they have a slide deck from an investor meeting in December 2022. They intend to launch their Proteome Analysis Platform in Mid-2024. They see a market opportunity of $25B, where 50% would be BioPharma customers, and 20% Academic and Research.

In #JPM2023 news, $SEER also presented. They are another of the Next Generation Proteomics Sequencing players. One of their USPs is that they have an approach capable of finding different protein variants that would be undistinguishable with affinity-based approaches. This includes slice variants, where the "Peptide Level" identification allows them to detect meaningful differences where other approaches are not able to.

In #JPM2023 news, $OLK Olink presented and showed good numbers, especially for their high-plex segment. Olink believes they have <5% penetration on the mid-plex TAM

Their estimated TAM is $85B, which is short of the other estimate touted at JPM for Proteomics as a whole, of $130B.

The SomaLogic technology binds SOMAmer reagents to thousands of individual proteins. The unbound proteins are washed away, and the SOMAmers are flown into an array that measures the relative concentration of the bound proteins with a colorimetric array.

They recently acquired $ISO Isoplexius, "the only single-cell platform enabling functional proteomics" (although people doing CITE-seq and co. on other single-cell technologies may differ).

In #JPM2023 news, $QSI Quantum-SI also presented on January 12, 2023. The company launched their Platinum protein sequencer a few weeks ago. The technology is not too dissimilar from the DNA sequencing Ion Torrent technology: a dense array of wells capture the proteins, then single molecule sequencing takes place independently in each well, and the different reactions for the different aminoacids are captured.

In #JPM2023 news, $ABSI Absci presented on Thursday 12, 2023. Also following the trend of asking AI what they should do, the company's Chief Morale Officer was put to the task of discovering biologics on a computer. Well, DALL-E's interpretation of that was on a slide. Absci has a slide about the "old paradigm" of drug discovery, focusing on #Antibody discovery. Either phages or mice are used to generate antibodies that bind to targets, and a process of optimization of affinity, toxicity and developability (how to produce large amounts of it)

In #JPM2023 news, $OMIC Singular Genomics presented on January 12, 2023. They see a 2022 TAM for NGS of $6B, growing to $20B in 2030. The G4 instrument is fast: it generates data at the same rate as a much bigger instrument in the NovaSeq 6000 but with SP flowcells, not the larger S4.

In #JPM2023 news, $NSTG NanoString presented on January 11, 2023. Started in single-cell gene expression, now expanding into #SpatialBiology. They see a $3B+$3B market opportunity both on the NGS-based and the Imaging-based tech respectively. The GeoMx is the NGS-based spatial biology solution, akin to the 10X Genomics Visium (and Visium HD in the future), with 25+ instruments in the pipe. CosMx is the imaging-based equivalent (Xenium in 10x portfolio), with about 80 instruments already in the pipe.